PE20020787A1 - 8-arilquinolina sustituida como inhibidores de fosfodiesterasa-4 - Google Patents
8-arilquinolina sustituida como inhibidores de fosfodiesterasa-4Info
- Publication number
- PE20020787A1 PE20020787A1 PE2001001261A PE2001001261A PE20020787A1 PE 20020787 A1 PE20020787 A1 PE 20020787A1 PE 2001001261 A PE2001001261 A PE 2001001261A PE 2001001261 A PE2001001261 A PE 2001001261A PE 20020787 A1 PE20020787 A1 PE 20020787A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroaryl
- aryl
- alkyl
- antagonist
- halogen
- Prior art date
Links
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- -1 C1-C6 ALKYL Inorganic materials 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 206010040070 Septic Shock Diseases 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical class O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010014824 Endotoxic shock Diseases 0.000 abstract 1
- 206010018691 Granuloma Diseases 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical compound C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA SAL DE ACIDO SULFURICO, METANSULFONICO, p-TOLUENSULFONICO, 2-NAFTALENSULFONICO, CLORHIDRICO, BENCENSULFONICO DE 8-ARILQUINOLINA SUSTITUIDA DE FORMULA I; DONDE S1, S2, S3 SON H, OH, HALOGENO, ALQUILO C1-C6, NO2, CN; ALCOXI C1-C6; R1 ES H, OH, HALOGENO, CARBONILO, ALQUILO C1-C6, CICLOALQUILO C3-C6, ALQUENILO C1-C6, ALCOXI C1-C6, ARILO, HETEROARILO, AMINO, ENTRE OTROS; A ES CH, C-ESTER, C-R4; R2 Y R3 SON ARILO, HETEROARILO, H, HALOGENO, CN, ENTRE OTROS; UNO DE R2 Y R3 ES ARILO O HETEROARILO O CUANDO R2 Y R3 SON AMBOS ARILO, HETEROARILO ESTAN OPTATIVAMENTE CONECTADOS MEDIANTE TIO, OXI, ALQUILO C1-C4, PARA FORMAR UN ANILLO DE TRES ANILLOS FUNDIDOS; R4 ES ARILO, ALQUILO C1-C6, HETEROARILO, CN, CARBONILO, CARBAMOILO, ENTRE OTROS; n ES 0-2; R2, R3, R4 PUEDEN FORMAR JUNTOS UN ANILLO. SON COMPUESTOS PREFERIDOS 6-[1-METIL-1-(METILSULFONIL)ETIL]-8-[3-[(E)-2-[3-METIL-1,2,4-OXADIAZOL-5-IL]-2-[4-(METILSULFONIL)FENIL]ETENIL]FENIL]QUINOLINA; QUE SE CARACTERIZAN POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE LEUCOTRIENO, INHIBIDOR DE LA BIOSINTESIS DE LEUCOTRIENO, ANTAGONISTA DE M2/M3, CORTICOSTEROIDE, ANTAGONISTA DEL RECEPTOR H1, AGONISTA DE RECEPTOR ß2-ADRENERGICO, INHIBIDOR DE COX-2, ESTATINA. LOS COMPUESTOS SON INHIBIDORES DE FOSFODIESTERASAS-4 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, GRANULOMA EOSINOFILO, PSORIASIS, CHOQUE ENDOTOXICO, CHOQUE SEPTICO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25680300P | 2000-12-20 | 2000-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020787A1 true PE20020787A1 (es) | 2002-09-10 |
Family
ID=22973639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001261A PE20020787A1 (es) | 2000-12-20 | 2001-12-17 | 8-arilquinolina sustituida como inhibidores de fosfodiesterasa-4 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6740666B2 (es) |
| EP (1) | EP1363635B1 (es) |
| JP (1) | JP2004521921A (es) |
| KR (1) | KR20030063456A (es) |
| CN (1) | CN100508978C (es) |
| AR (1) | AR035514A1 (es) |
| AT (1) | ATE428420T1 (es) |
| AU (1) | AU2001297603B2 (es) |
| BG (1) | BG107900A (es) |
| BR (1) | BR0116372A (es) |
| CA (1) | CA2431549A1 (es) |
| CZ (1) | CZ20031738A3 (es) |
| DE (1) | DE60138421D1 (es) |
| DO (1) | DOP2001000308A (es) |
| EA (1) | EA006607B1 (es) |
| EE (1) | EE200300266A (es) |
| HU (1) | HUP0400654A3 (es) |
| IL (1) | IL156479A0 (es) |
| JO (1) | JO2317B1 (es) |
| MX (1) | MXPA03005673A (es) |
| MY (1) | MY136792A (es) |
| NO (1) | NO20032807L (es) |
| NZ (1) | NZ526376A (es) |
| PE (1) | PE20020787A1 (es) |
| PL (1) | PL362564A1 (es) |
| SK (1) | SK7732003A3 (es) |
| WO (1) | WO2002069970A1 (es) |
| ZA (1) | ZA200304672B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03005571A (es) * | 2000-12-20 | 2003-10-06 | Merck & Co Inc | Procedimiento para preparar bencenosulfonato de 8-arilquinolinio sustituido. |
| US7144896B2 (en) | 2002-03-18 | 2006-12-05 | Merck Frosst Canada Ltd. | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
| WO2004071435A2 (en) * | 2003-02-10 | 2004-08-26 | Todd Ovokaitys | Enhanced Bioavailability Using Laser Resonant Homogenization |
| GB0307863D0 (en) * | 2003-04-04 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic treatment |
| US20050014729A1 (en) * | 2003-07-16 | 2005-01-20 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| CN100425591C (zh) * | 2005-09-26 | 2008-10-15 | 山东大学 | 含有磺酰基二苯基乙烯桥化合物及其制法和药物应用 |
| EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| BRPI0713768A2 (pt) | 2006-07-05 | 2012-10-30 | Nycomed Gmbh | combinação de inibidores de reductase de hmg-coa com inibidores de fosfodiesterase 4 para o tratamento de doenças pulmonares inflamatórias |
| CA2657093A1 (en) * | 2006-07-07 | 2008-01-10 | Steven P. Govek | Bicyclic heteroaryl inhibitors of pde4 |
| WO2008127975A2 (en) * | 2007-04-11 | 2008-10-23 | Alcon Research, Ltd. | Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis |
| US20090182035A1 (en) * | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
| CN103351390A (zh) * | 2007-11-21 | 2013-10-16 | 解码遗传Ehf公司 | 用于治疗肺部和心血管病症的联芳基pde4 抑制剂 |
| JP5721722B2 (ja) * | 2009-10-01 | 2015-05-20 | アルコン リサーチ， リミテッド | オロパタジン組成物およびその使用 |
| US8367829B2 (en) | 2010-05-10 | 2013-02-05 | Gilead Sciences, Inc. | Bi-functional pyrazolopyridine compounds |
| JP5807058B2 (ja) | 2010-05-10 | 2015-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | 二機能キノリン誘導体 |
| JP2022515838A (ja) | 2018-12-28 | 2022-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アラキドン酸１５－リポキシゲナーゼ（ａｌｏｘ１５）阻害剤による呼吸器障害の治療 |
| WO2022212488A1 (en) * | 2021-03-31 | 2022-10-06 | Riboscience Llc | Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9212673D0 (en) | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| GB9212693D0 (en) | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| ATE144248T1 (de) | 1992-07-01 | 1996-11-15 | Hoechst Ag | 3,4,5-substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
| GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| DE4306152A1 (de) | 1993-02-27 | 1994-09-01 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9326699D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
| GB9326173D0 (en) | 1993-12-22 | 1994-02-23 | Celltech Ltd | Chemical compounds and process |
| WO1995017399A1 (en) | 1993-12-22 | 1995-06-29 | Celltech Therapeutics Limited | Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors |
| US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
| GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| EP0765867A1 (de) | 1995-09-27 | 1997-04-02 | Hoechst Aktiengesellschaft | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Antiarrhytmika oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9526246D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9526243D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| DE19622370A1 (de) | 1996-06-04 | 1997-12-11 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
| PL334059A1 (en) | 1996-12-11 | 2000-01-31 | Basf Ag | Ketone benzamides useful as calpain inhibitors |
| JPH11209350A (ja) | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| US6410563B1 (en) * | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| MY134008A (en) * | 1999-12-22 | 2007-11-30 | Merck Frosst Canada Inc | Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors |
| JP4415360B2 (ja) | 2000-01-28 | 2010-02-17 | エプソントヨコム株式会社 | 縦結合弾性表面波フィルタ |
-
2001
- 2001-11-09 US US10/040,993 patent/US6740666B2/en not_active Expired - Fee Related
- 2001-12-10 AR ARP010105722A patent/AR035514A1/es not_active Application Discontinuation
- 2001-12-11 MY MYPI20015614A patent/MY136792A/en unknown
- 2001-12-11 JO JO2001195A patent/JO2317B1/en active
- 2001-12-14 KR KR10-2003-7008443A patent/KR20030063456A/ko not_active Withdrawn
- 2001-12-14 EA EA200300706A patent/EA006607B1/ru not_active IP Right Cessation
- 2001-12-14 CA CA002431549A patent/CA2431549A1/en not_active Abandoned
- 2001-12-14 PL PL01362564A patent/PL362564A1/xx unknown
- 2001-12-14 NZ NZ526376A patent/NZ526376A/en unknown
- 2001-12-14 CN CNB018227600A patent/CN100508978C/zh not_active Expired - Fee Related
- 2001-12-14 AT AT01273908T patent/ATE428420T1/de not_active IP Right Cessation
- 2001-12-14 EP EP01273908A patent/EP1363635B1/en not_active Expired - Lifetime
- 2001-12-14 DE DE60138421T patent/DE60138421D1/de not_active Expired - Fee Related
- 2001-12-14 AU AU2001297603A patent/AU2001297603B2/en not_active Ceased
- 2001-12-14 MX MXPA03005673A patent/MXPA03005673A/es active IP Right Grant
- 2001-12-14 CZ CZ20031738A patent/CZ20031738A3/cs unknown
- 2001-12-14 SK SK773-2003A patent/SK7732003A3/sk unknown
- 2001-12-14 EE EEP200300266A patent/EE200300266A/xx unknown
- 2001-12-14 HU HU0400654A patent/HUP0400654A3/hu unknown
- 2001-12-14 IL IL15647901A patent/IL156479A0/xx unknown
- 2001-12-14 JP JP2002569145A patent/JP2004521921A/ja not_active Withdrawn
- 2001-12-14 BR BR0116372-8A patent/BR0116372A/pt not_active IP Right Cessation
- 2001-12-14 WO PCT/US2001/048674 patent/WO2002069970A1/en not_active Ceased
- 2001-12-17 PE PE2001001261A patent/PE20020787A1/es not_active Application Discontinuation
- 2001-12-18 DO DO2001000308A patent/DOP2001000308A/es unknown
-
2003
- 2003-06-11 BG BG107900A patent/BG107900A/bg unknown
- 2003-06-17 ZA ZA200304672A patent/ZA200304672B/en unknown
- 2003-06-19 NO NO20032807A patent/NO20032807L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03005673A (es) | 2003-10-06 |
| EP1363635B1 (en) | 2009-04-15 |
| PL362564A1 (en) | 2004-11-02 |
| JP2004521921A (ja) | 2004-07-22 |
| CN100508978C (zh) | 2009-07-08 |
| DOP2001000308A (es) | 2002-07-15 |
| CN1551769A (zh) | 2004-12-01 |
| AR035514A1 (es) | 2004-06-02 |
| ATE428420T1 (de) | 2009-05-15 |
| EE200300266A (et) | 2003-10-15 |
| US20020143032A1 (en) | 2002-10-03 |
| NO20032807D0 (no) | 2003-06-19 |
| EA006607B1 (ru) | 2006-02-24 |
| KR20030063456A (ko) | 2003-07-28 |
| DE60138421D1 (en) | 2009-05-28 |
| NO20032807L (no) | 2003-08-15 |
| ZA200304672B (en) | 2004-04-21 |
| EA200300706A1 (ru) | 2003-12-25 |
| EP1363635A1 (en) | 2003-11-26 |
| JO2317B1 (en) | 2005-09-12 |
| MY136792A (en) | 2008-11-28 |
| HUP0400654A2 (hu) | 2004-06-28 |
| SK7732003A3 (en) | 2003-11-04 |
| NZ526376A (en) | 2005-02-25 |
| BR0116372A (pt) | 2003-12-09 |
| US6740666B2 (en) | 2004-05-25 |
| CZ20031738A3 (cs) | 2003-11-12 |
| HUP0400654A3 (en) | 2011-07-28 |
| CA2431549A1 (en) | 2002-09-12 |
| BG107900A (bg) | 2004-06-30 |
| AU2001297603B2 (en) | 2006-02-16 |
| IL156479A0 (en) | 2004-01-04 |
| WO2002069970A1 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020787A1 (es) | 8-arilquinolina sustituida como inhibidores de fosfodiesterasa-4 | |
| AU2007311087B2 (en) | Organic compounds | |
| ES2729424T3 (es) | Inhibidores de Rho cinasa | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| PE20030416A1 (es) | 1,8-naftiridin-4(1h)-onas alquin aril sustituidas como inhibidores de fosfodiesterasa-4 | |
| CN105272904B (zh) | N-苯基酰胺类化合物及其应用 | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| PE20011115A1 (es) | Etanos tri-aril-sustituidos inhibidores de pde4 | |
| ES2865182T3 (es) | Inhibidor de URAT1 | |
| NO20075384L (no) | Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer. | |
| SG181734A1 (en) | Substituted isoquinolinones and quinazolinones | |
| CA2426440A1 (en) | Quinazoline derivatives as kinase inhibitors | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
| ME02323B (me) | Spiro supstituisana jedinjenja kao inhibitori angiogeneze | |
| NO20053960L (no) | Piperidin-benzensulfonamidderivater | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| HRP20041005A2 (en) | Quinoline and isoquinoline derivatives, method forthe production thereof and use thereof as anti-inflammatory agents | |
| CO6220952A2 (es) | Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
| ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| MY140070A (en) | 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| WO2008051533A3 (en) | Benzimidazole compounds | |
| AR054021A1 (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
| MA30420B1 (fr) | Derives de terphenyle pour le traitment de la maladie d'alzheimer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |